US Stock MarketDetailed Quotes

RNAC Cartesian Therapeutics

Watchlist
  • 14.360
  • -0.520-3.49%
Close Mar 27 16:00 ET
372.03MMarket Cap-3.20P/E (TTM)

Cartesian Therapeutics Key Stats

Cartesian Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 8 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 687.500K--
--2025/Q1-- / 687.500K--
--2024/Q4-759.000K / 100.000K--
--2024/Q3387.000K / 1.833M--
--2024/Q233.445M / 5.506M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 687.500K--
--2025/Q1-- / 687.500K--
--2024/Q4-759.000K / 100.000K--
--2024/Q3387.000K / 1.833M--
--2024/Q233.445M / 5.506M--

Unlock Free Earnings Estimates

Cartesian Therapeutics Earnings Reports

Read more

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More